Cancer drug spending surges to $100B in 2014 - SPDR Biotech ETF (NYSEARCA:XBI) | Seeking Alpha To screen ETFs by asset class, performance, yield and more, check out the ETF Hub. ETF Hub May  5 2015, 04:09 ET | By: Yoel Minkoff , SA News Editor Global annual spending on cancer drugs in 2014 hit $100B (+10% Y/Y) for the first time, largely due to rising drug prices and increased incidence of cancer. "Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer," the IMS said in a report . The figures raise even more questions of affordability as the pharmaceuticals industry prepares to launch a fresh generation of treatments that promise to push costs even higher. Related: U.S. drug spending rose 13% in 2014 (Apr. 14 2015) Related: Is hefty specialty drug spending the new normal? (Mar. 10 2015) ETF Performance: View ETF performance across key asset classes and investing themes 